曲美他嗪治疗慢性心力衰竭疗效观察

Clinical observation on trimetazidine in treatment of chronic heart failure

目的观察曲美他嗪（TMZ）治疗慢性心力衰竭（CHF）的临床疗效。方法70例CHF患者随机分为对照组和治疗组各35例，对照组给予抗心力衰竭常规治疗，治疗组在对照组的基础上加用TMZ。20mg／次，3次／d。8周后观察比较两组心功能改善情况。结果治疗组治疗前左室射血分数（LVEF）（38．0±2．4）％，治疗后LVEF（48．0±2．3）％；对照组治疗前LVEF（38．2±2．2）％，治疗后LVEF（42．0±2．5）％；两组LVEF治疗前后差异均有统计学意义（t=6．9419、2．8482，均P〈0．05）；治疗组治疗后较对照组改善更明显（t=4．3147，P〈0．05）。对照组再住院10例（28．5％），治疗组再住院3例（8．5％），两组再住院率差异有统计学意义（χ2=4．629，P〈0．05）。两组均未见死亡病例，均未发生严重不良反应。结论在常规抗心衰治疗的基础上加用TMZ可显著改善慢性心力衰竭患者的心功能，降低再住院率。

Objective To explore the clinical effect of chlorpromazine （TMZ） in treatment of chronic heart failure（CHF）. Methods 70 patients with CHF were randomly divided into control group and treatment group 35 cases in each gronp,eontrol group was given conventional treatment,treatment group on the basis of additional application TMZ,20mg/times,3 times/d. 8 weeks after the observation and comparison of two groups of cardiac function in improving the situation. Results Treatment group before the treatment of LVEF （ 38.0 ± 2.4） % After treatment, LVEF （ 48.0 ± 2.3 ） % ; control group before treatment LVEF （ 38.2 ± 2.2） % after treatment, LVEF （ 42.0±2.5 ） % ; Twosetsoftreatment LVEFdifference statistically significant （ t = 6. 9419,2. 8482, allP 〈 0.05 ） ; Treatment group compared with control groups after treatment improve even more obvious （t = 4.3147, P 〈 0. 05 ） o Control groups and then hospitalized 10 cases（28.5% ） ,the treatment group hospitalization 3 cases（8.5% ） ,both groups rate difference statistically significant（ χ2 = 4.629 ,P 〈 0.05）. Both groups were no deaths,no serious adverse effects. Conclusion General against heart failure therapy on the basis of the combined with TMZ could significantly improve the cardiac function of patients with chronic heart failure, reducing hospitalization rates.